571,825 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 571,825 shares of the company’s stock, valued at approximately $49,943,000. Protagonist Therapeutics accounts for about 4.4% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings, making the stock its 7th largest holding.

Several other institutional investors also recently added to or reduced their stakes in PTGX. Royal Bank of Canada increased its stake in Protagonist Therapeutics by 30.6% in the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock worth $482,000 after buying an additional 2,334 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Protagonist Therapeutics by 0.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after buying an additional 348 shares during the period. Millennium Management LLC increased its stake in Protagonist Therapeutics by 283.6% in the 1st quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock worth $6,493,000 after buying an additional 99,269 shares during the period. Arrowstreet Capital Limited Partnership purchased a new position in Protagonist Therapeutics in the 2nd quarter worth about $987,000. Finally, Guggenheim Capital LLC increased its stake in Protagonist Therapeutics by 1.6% in the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock worth $1,062,000 after buying an additional 303 shares during the period. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Performance

NASDAQ PTGX opened at $105.77 on Thursday. The company has a market capitalization of $6.80 billion, a price-to-earnings ratio of -58.44 and a beta of 1.85. The company’s 50-day simple moving average is $101.50 and its two-hundred day simple moving average is $92.93. Protagonist Therapeutics, Inc. has a one year low of $49.38 and a one year high of $111.45.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The business had revenue of $56.37 million for the quarter, compared to the consensus estimate of $11.70 million. Equities analysts expect that Protagonist Therapeutics, Inc. will post 2.93 earnings per share for the current fiscal year.

Insider Transactions at Protagonist Therapeutics

In other news, Director Bryan Giraudo sold 36,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $100.14, for a total value of $3,605,040.00. Following the transaction, the director owned 27,825 shares of the company’s stock, valued at $2,786,395.50. The trade was a 56.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Asif Ali sold 24,765 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $104.24, for a total transaction of $2,581,503.60. Following the completion of the transaction, the chief financial officer directly owned 60,753 shares in the company, valued at approximately $6,332,892.72. The trade was a 28.96% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 263,345 shares of company stock worth $26,707,266. 5.19% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PTGX. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $110.00 price target on shares of Protagonist Therapeutics in a research note on Wednesday, May 6th. Citizens Jmp raised their price target on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Wedbush raised their target price on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Jefferies Financial Group reissued a “buy” rating and set a $121.00 target price on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. Finally, Leerink Partners raised their target price on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Protagonist Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $115.21.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.